Back to Search Start Over

Antibodies against nonstructural protein 1 protect mice from dengue virus-induced mast cell activation

Authors :
Chu, Ya-Ting
Wan, Shu-Wen
Chang, Yu-Chang
Lee, Chien-Kuo
Wu-Hsieh, Betty A
Anderson, Robert
Lin, Yee-Shin
Source :
Laboratory Investigation; May 2017, Vol. 97 Issue: 5 p602-614, 13p
Publication Year :
2017

Abstract

Dengue virus (DENV) infection causes dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). DHF/DSS patients have been reported to have increased levels of urinary histamine, chymase, and tryptase, which are major granule-associated mediators from mast cells. Previous studies also showed that DENV-infected human mast cells induce production of proinflammatory cytokines and chemokines, suggesting a role played by mast cells in vascular perturbation as well as leukocyte recruitment. In this study, we show that DENV but not UV-inactivated DENV enhanced degranulation of mast cells and production of chemokines (MCP-1, RANTES, and IP-10) in a mouse model. We have previously shown that antibodies (Abs) against a modified DENV nonstructural protein 1 (NS1), designated DJ NS1, provide protection in mice against DENV challenge. In the present study, we investigate the effects of DJ NS1 Abs on mast cell-associated activities. We showed that administration of anti-DJ NS1 Abs into mice resulted in a reduction of mast cell degranulation and macrophage infiltration at local skin DENV infection sites. The production of DENV-induced chemokines (MCP-1, RANTES, and IP-10) and the percentages of tryptase-positive activated mast cells were also reduced by treatment with anti-DJ NS1 Abs. These results indicate that Abs against NS1 protein provide multiple therapeutic benefits, some of which involve modulating DENV-induced mast cell activation.

Details

Language :
English
ISSN :
00236837 and 15300307
Volume :
97
Issue :
5
Database :
Supplemental Index
Journal :
Laboratory Investigation
Publication Type :
Periodical
Accession number :
ejs41819166
Full Text :
https://doi.org/10.1038/labinvest.2017.10